Telix Pharmaceuticals Ltd has released a press release.
NDA for Prostate Cancer Imaging accepted by US FDA
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Investor Briefing - Asia Strategy
- Strategic Licence and Partnership for Greater China Market
- App 4C and Activities Report for September 2020 Quarter
- FDA grants Orphan Drug Designation for glioma imaging agent
- Telix submits NDA to US FDA for Prostate Cancer Imaging
Later from Telix Pharmaceuticals
- Prostate Cancer Therapy FDA Meeting Update
- Telix Acquires TheraPharm GmbH
- Acquisition of TheraPharm GmbH - Investor Call
- Briefing for Investor call - TheraPharm GmbH Acquisition
- Telix and DuChemBio - South Korea Partnership
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals